Literature DB >> 15135517

Evaluation of three serum i-ELISAs using monoclonal antibodies and protein G as peroxidase conjugate for the diagnosis of bovine brucellosis.

C Saegerman1, L De Waele, D Gilson, J Godfroid, P Thiange, P Michel, B Limbourg, T K-O Vo, J Limet, J-J Letesson, D Berkvens.   

Abstract

Three i-ELISAs using LPS, the immunodominant component of Brucella abortus, were developed with three different conjugates: monoclonal antibodies 1C8 (anti-bovine IgG(1)) and 3H3 (mainly specific for bovine IgG(2) but also reacting with IgG(1)) and protein G (reacts with both bovine IgG subclasses). Using a cut-off value of 2.5U/ml, the i-ELISA with 3H3 as conjugate had a specificity (95% CI: 98.32-99.63%) that was significantly higher than the same assay with 1C8 (95% CI: 96.08-98.26%) or PG (95% CI: 95.83-98.09%). In areas where false positive serological reactions (FPSR) were common, the specificity of the i-ELISAs decreased significantly. The specificity of the i-ELISAs increased with the age of the animals tested, irrespective of the conjugate. The specificity of the i-ELISAs and traditional tests was also examined using sera from animals infected per os with bacteria bearing LPS similar to the Brucella LPS. It appeared that Yersinia enterocolitica O:9, Xanthomonas maltophilia and Salmonella urbana infections induced FPSR both in the i-ELISAs and in the traditional tests, but the 3H3 assay was significantly less prone to produce false positive reactions than the 1C8 and PG assays. The i-ELISAs were more sensitive, allowed earlier detection, and were more persistent than the traditional serological tests both in experimentally and naturally Brucella-infected animals. Weekly i-ELISA monitoring of experimentally infected pregnant heifers (previously vaccinated or not) allowed a prediction of abortion. Furthermore, the 1C8 assay showed significantly higher titres irrespective of day post-infection and vaccination status. The accuracy of the assay could be improved by making use of additional information (e.g. animal age or conjugate) and by selecting appropriate cut-off points on the basis of the prevailing epidemiological situation. The i-ELISAs appear an appropriate choice in order to maintain an official brucellosis-free status because of their sensitivity, early detection and long persistence and, for the same reasons, seem especially valuable for the detection of latent carriers (i.e. animals classified negative by classical serological tests) among imported animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135517     DOI: 10.1016/j.vetmic.2004.02.003

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  16 in total

1.  Improvement in the diagnosis of Brucella abortus infections in naturally infected water buffaloes (Bubalus bubalis) using an ELISA with a Protein-G-based indicator system.

Authors:  Manish Kumar; Puran Chand
Journal:  Trop Anim Health Prod       Date:  2011-03-27       Impact factor: 1.559

2.  Bayesian Evaluation of Three Serological Tests for Detecting Antibodies against Brucella spp. among Humans in the Northwestern Part of Ecuador.

Authors:  Jorge Ron-Román; Lenin Ron-Garrido; Emmanuel Abatih; Maritza Celi-Erazo; Laura Vizcaíno-Ordóñez; Jaime Calva-Pacheco; Pablo González-Andrade; Dirk Berkvens; Washington Benítez-Ortíz; Jef Brandt; David Fretin; Claude Saegerman
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

3.  Evaluation of indirect enzyme-linked immunosorbent assays and IgG avidity assays using a protein A-peroxidase conjugate for serological distinction between Brucella abortus S19-vaccinated and -infected cows.

Authors:  Ana C A M Pajuaba; Deise A O Silva; José R Mineo
Journal:  Clin Vaccine Immunol       Date:  2010-02-10

Review 4.  Diagnosis of brucellosis in livestock and wildlife.

Authors:  Jacques Godfroid; Klaus Nielsen; Claude Saegerman
Journal:  Croat Med J       Date:  2010-08       Impact factor: 1.351

5.  Serological diagnosis of Brucella infections in odontocetes.

Authors:  Gabriela Hernández-Mora; Charles A Manire; Rocío González-Barrientos; Elías Barquero-Calvo; Caterina Guzmán-Verri; Lydia Staggs; Rachel Thompson; Esteban Chaves-Olarte; Edgardo Moreno
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

6.  True versus apparent malaria infection prevalence: the contribution of a Bayesian approach.

Authors:  Niko Speybroeck; Nicolas Praet; Filip Claes; Nguyen Van Hong; Kathy Torres; Sokny Mao; Peter Van den Eede; Ta Thi Thinh; Dioni Gamboa; Tho Sochantha; Ngo Duc Thang; Marc Coosemans; Philippe Büscher; Umberto D'Alessandro; Dirk Berkvens; Annette Erhart
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  An evaluation of Irish cattle herds with inconclusive serological evidence of bovine brucellosis.

Authors:  M Hayes; S Ashe; Dm Collins; S Power; K Kenny; M Sheahan; G O'Hagan; Sj More
Journal:  Ir Vet J       Date:  2009-03-01       Impact factor: 2.146

8.  Development of an improved competitive ELISA based on a monoclonal antibody against lipopolysaccharide for the detection of bovine brucellosis.

Authors:  Xiaolei Wang; Yan Wang; Limei Ma; Ran Zhang; Yanyan De; Xiaowen Yang; Chuanqing Wang; Qingmin Wu
Journal:  BMC Vet Res       Date:  2015-05-21       Impact factor: 2.741

9.  Seroprevalence and potential risk factors for Brucella spp. infection in traditional cattle, sheep and goats reared in urban, periurban and rural areas of Niger.

Authors:  Abdou Razac Boukary; Claude Saegerman; Emmanuel Abatih; David Fretin; Rianatou Alambédji Bada; Reginald De Deken; Halimatou Adamou Harouna; Alhassane Yenikoye; Eric Thys
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 10.  Evaluation of Immunofluorescence Antibody Test Used for the Diagnosis of Canine Leishmaniasis in the Mediterranean Basin: A Systematic Review and Meta-Analysis.

Authors:  Amel Adel; Dirk Berkvens; Emmanuel Abatih; Abdelkrim Soukehal; Juana Bianchini; Claude Saegerman
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.